Americas Committee for Treatment and Research in Multiple Sclerosis

Mary Rensel, MD: Transitioning to Shared Medical Appointments

April 02, 2020

The director of Pediatric MS and Wellness programming at the Mellen Center and assistant professor of neurology at Cleveland Clinic Lerner College of Medicine discussed the harsh realities of patients adopting a new treatment method.

Le Hua, MD: Siponimod in Secondary Progressive Multiple Sclerosis

March 25, 2020

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed what can currently be surmised about siponimod’s effect in treating patients with SPMS.

Le Hua, MD: Subanalysis of the EXPAND Study of Siponimod in SPMS

March 24, 2020

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the findings of a subanalysis of the EXPAND study of siponimod in patients with secondary progressive multiple sclerosis.

Le Hua, MD: Considering Age in Multiple Sclerosis Treatment

March 19, 2020

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the need to take age into consideration when managing a patient with MS, and how the thinking about the disease and age has shifted.

Le Hua, MD: Disease Duration and Age in MS

March 18, 2020

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed the current thinking about the challenges of addressing multiple sclerosis in older patients.

Robert Glanzman, MD: Overview of CNM-Au8

March 17, 2020

The chief medical officer of Clene Nanomedicine detailed CNM-Au8, their novel investigational drug currently being assessed in multiple trials for patients with multiple sclerosis and other neurodegenerative diseases.